Axcella Health Inc. (NASDAQ:AXLA) Sees Significant Decrease in Short Interest

Axcella Health Inc. (NASDAQ:AXLAGet Rating) saw a significant drop in short interest during the month of August. As of August 31st, there was short interest totalling 96,500 shares, a drop of 7.8% from the August 15th total of 104,700 shares. Currently, 0.5% of the shares of the company are short sold. Based on an average daily volume of 69,100 shares, the days-to-cover ratio is currently 1.4 days.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on AXLA shares. Wedbush dropped their target price on shares of Axcella Health to $7.00 in a report on Friday, May 27th. HC Wainwright dropped their price target on shares of Axcella Health from $14.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, August 3rd. Finally, SVB Leerink dropped their price target on shares of Axcella Health from $9.00 to $6.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 3rd. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $6.50.

Axcella Health Stock Performance

Shares of NASDAQ AXLA opened at $2.11 on Tuesday. The company has a debt-to-equity ratio of 2.33, a quick ratio of 2.69 and a current ratio of 2.69. The company has a market cap of $110.94 million, a P/E ratio of -1.22 and a beta of 1.10. The firm’s fifty day moving average is $2.20 and its two-hundred day moving average is $2.12. Axcella Health has a 52-week low of $1.35 and a 52-week high of $4.40.

Axcella Health (NASDAQ:AXLAGet Rating) last posted its earnings results on Friday, August 12th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.04). As a group, analysts anticipate that Axcella Health will post -1.55 EPS for the current fiscal year.

Institutional Trading of Axcella Health

A number of large investors have recently made changes to their positions in AXLA. Pinnacle Private Wealth LLC increased its holdings in shares of Axcella Health by 43.9% in the 1st quarter. Pinnacle Private Wealth LLC now owns 29,500 shares of the company’s stock worth $76,000 after buying an additional 9,000 shares during the last quarter. Edgewood Management LLC boosted its stake in shares of Axcella Health by 33.3% during the 1st quarter. Edgewood Management LLC now owns 100,000 shares of the company’s stock worth $257,000 after purchasing an additional 25,000 shares during the period. Flagship Pioneering Inc. boosted its stake in shares of Axcella Health by 50.4% during the 1st quarter. Flagship Pioneering Inc. now owns 18,867,785 shares of the company’s stock worth $48,490,000 after purchasing an additional 6,319,371 shares during the period. HarbourVest Partners LLC boosted its stake in shares of Axcella Health by 55.9% during the 1st quarter. HarbourVest Partners LLC now owns 4,378,661 shares of the company’s stock worth $11,253,000 after purchasing an additional 1,570,680 shares during the period. Finally, FMR LLC boosted its stake in shares of Axcella Health by 1.1% during the 2nd quarter. FMR LLC now owns 7,886,376 shares of the company’s stock worth $16,009,000 after purchasing an additional 85,541 shares during the period. 64.81% of the stock is currently owned by institutional investors.

Axcella Health Company Profile

(Get Rating)

Axcella Health Inc operates as a clinical stage biotechnology company in the United States. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence; and AXA1125 that is in Phase 2b clinical trial for treating non-alcoholic steatohepatitis, as well as in Phase 2a clinical trial for Long COVID therapy for patients.

Featured Stories

Receive News & Ratings for Axcella Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axcella Health and related companies with MarketBeat.com's FREE daily email newsletter.